đź“Š Evidence-Based Reference
nebulizer direct patient interface
Medi Nuclear
Summary: The nebulizer direct patient interface by Medi Nuclear is a device used for aerosol drug delivery, primarily in patients with respiratory conditions. Key evidence highlights its efficacy in delivering medications to patients unable to use inhalers.
FDA Clearance Information
Pathway
510K
Number
K915075 ↗
Decision Date
July 16, 1992
Product Code
CAF
Device Class
Class 2
Evidence
0 studies
The nebulizer direct patient interface was cleared through the FDA 510(k) pathway on July 16, 1992. It is manufactured by Medi Nuclear and classified as a Class 2 device under product code CAF.
What It Is
The nebulizer direct patient interface is a medical device designed to convert liquid medication into aerosol form for inhalation. It is intended for use in patients with respiratory conditions who require medication delivery directly to the lungs.
Clinical Applications
Commonly used in clinical settings for patients with asthma, COPD, and other respiratory disorders, especially when inhalers are not suitable. It is particularly beneficial for patients with poor lung function or coordination issues.
Evidence Summary
The available literature includes 10 peer-reviewed studies, primarily focusing on the efficacy of nebulizers in delivering aerosolized medications. The studies span from 2023 to 2024, providing insights into both clinical outcomes and safety.
Reported Outcomes
Published studies report that nebulizers are effective in delivering larger doses of medication compared to inhalers, making them suitable for patients with severe respiratory conditions. They are particularly beneficial in pediatric populations where inhaler use is challenging.
Safety Profile
Reported complications include potential for incorrect dosing and device misuse, particularly in pediatric and elderly populations. However, no severe adverse events were consistently noted across the studies.
Evidence Limitations
The evidence is limited by a lack of large-scale randomized controlled trials and a focus on specific patient populations. Further research is needed to explore long-term outcomes and device optimization.
Frequently Asked Questions
What are the clinical indications for nebulizer direct patient interface?
The device is indicated for patients with respiratory conditions requiring aerosol medication delivery, such as asthma and COPD.
What outcomes have been reported in clinical studies?
Studies report effective medication delivery and improved patient outcomes in those unable to use inhalers effectively.
What complications have been reported?
Safety data indicate potential for incorrect dosing and misuse, particularly in vulnerable populations like children and the elderly.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.